Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis

Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis

Objective: Cutaneous immune-related adverse events (cirAEs) represent a prevalent manifestation of adverse reactions linked to immune checkpoint inhibitors (ICIs) therapy, substantially affecting patients’ quality of life. This systematic review and meta-analysis aimed to quantify the pooled inciden...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhihui Yang, Yuanyuan Luo, Ruiqi Lu, Xinqi Liu, Hanyu Liu, Suting Liu, Chen Huang, Jinhui Tian, Lili Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Current Oncology
Subjects:	immune checkpoint inhibitors meta-analysis cutaneous immune-related adverse events
Online Access:	https://www.mdpi.com/1718-7729/32/4/195
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events
by: Giacomo Triggiano, et al.
Published: (2025-04-01)

Cutaneous adverse events due to checkpoint inhibitors – a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022
by: Clara Furrer-Matcau, et al.
Published: (2024-12-01)

Spontaneous haematoma: A unique immune-related adverse event alongside other cutaneous reactions in a patient treated with pembrolizumab for metastatic melanoma
by: Dalila Malek, et al.
Published: (2024-12-01)

Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic
by: Sakiko Kimura, et al.
Published: (2025-04-01)

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
by: E. A. Degtiareva, et al.
Published: (2022-11-01)

Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysis
by: Jiayang Yu, et al.
Published: (2025-04-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
by: Jiayi Gao, et al.
Published: (2025-02-01)

Construction of predictive model for programmed death-1 inhibitor-related endocrine adverse events
by: Jiaying SHI, et al.
Published: (2025-08-01)

Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization
by: Liuliu Quan, et al.
Published: (2024-12-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01)

Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xiaoqing Zhou, et al.
Published: (2025-05-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma
by: Raphaella Lambert, BA, et al.
Published: (2025-04-01)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
by: Ting Zhang, et al.
Published: (2025-03-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

Prevention and management of immune-related adverse events for biliary tract cancers
by: LIU Kun, GUO Wei
Published: (2025-03-01)

A systematic review of gastritis as an immune-related adverse event in clinical interventions
by: Fei Su, et al.
Published: (2024-12-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy
by: Arian Lasocki, et al.
Published: (2025-06-01)

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
by: Nora Möhn, et al.
Published: (2025-12-01)

Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis
by: Qimei Fang, et al.
Published: (2025-02-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge
by: Ying-Jie Su, et al.
Published: (2025-08-01)

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy
by: Tatsushi Kawada, et al.
Published: (2025-07-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
by: Natalie Bourand, MS, et al.
Published: (2025-02-01)

Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review
by: Shion Kachi, et al.
Published: (2025-08-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
by: Maria Luisa De Perna, et al.
Published: (2025-08-01)

Reporting of immune-related adverse events in US Food and Drug Administration approvals of immune checkpoint inhibitors
by: Shaili Tapiavala, et al.
Published: (2025-08-01)

Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
by: Michael Sayer, et al.
Published: (2025-04-01)

Natural killer cell as a potential predictive biomarker for early immune checkpoint inhibitor-associated cardiovascular adverse events: a retrospective cohort study
by: Yujuan Wu, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
by: Xueqian Mao, et al.
Published: (2025-06-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Immune-Related Adverse Events in a Patient Treated with Pembrolizumab: A Case Report from the Point of View of a Geriatrician
by: Philipp Oft, et al.
Published: (2024-12-01)

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database
by: Huiping Zhang, et al.
Published: (2025-08-01)